Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trospium chloride/xanomeline - Karuna Therapeutics

X
Drug Profile

Trospium chloride/xanomeline - Karuna Therapeutics

Alternative Names: BMS-986510; COBENFY; Karuna-Xanomeline-Trospium - Karuna Therapeutics; KarXT - Karuna Therapeutics; Trospium chloride/LY-246708 - Karuna Therapeutics; Trospium chloride/xanomeline tartrate - Karuna Therapeutics; Xanomeline tartrate/ trospium chloride - Karuna Therapeutics; Xanomeline/trospium chloride - Karuna Therapeutics

Latest Information Update: 23 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PureTech Health
  • Developer Karuna Therapeutics; ZAI Lab
  • Class Analgesics; Antidementias; Antipsychotics; Antispasmodics; Benzhydryl compounds; Benzilates; Esters; Nortropanes; Pyridines; Small molecules; Spiro compounds; Thiadiazoles; Urologics
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Schizophrenia
  • Phase III Psychotic disorders
  • Discontinued Pain

Most Recent Events

  • 17 Jan 2025 Preregistration for Schizophrenia in China (PO)
  • 17 Jan 2025 The NMPA accepts NDA for trospium chloride/xanomeline for Schizophrenia for review
  • 12 Dec 2024 Karuna Therapeutics plans a phase I pharmacokinetics trial (In volunteers) in USA, in December 2024 (NCT06729970)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top